YYForce subsidiary Xtreme Solution posts SGD 288,825 profit for year ended March 31, 2026
Bitget2026/10/02 20:11- Xtreme Solution, a YYForce subsidiary, posted revenue of SGD 5.83 million for the year ended March 31, 2026, down from SGD 6.44 million.
- Net profit fell to SGD 288,825 from SGD 540,649; profit before tax dropped to SGD 335,014 from SGD 641,818.
- Total assets rose to SGD 3.79 million from SGD 3.4 million; equity climbed to SGD 715,557 from SGD 227,847.
- Bank loans declined to SGD 2.28 million from SGD 2.51 million; cash ended at SGD 137,632 versus SGD 195,162.
- Property was revalued to SGD 1.8 million, generating OCI of SGD 198,885 net of deferred tax.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
Crypto prices
More
